AUPH Aurinia Pharmaceuticals
- 9.030
- -0.010-0.11%
- 9.030
- 0.0000.00%
Aurinia Pharmaceuticals News
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Siemens Healthineers AG (OtherSEMHF)
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $10.85
Leerink Partners Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
Bloom Burton Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Raises Target Price to $9.4
Aurinia Pharmaceuticals: Strategic Growth and Buy Rating Amidst Japan Market Expansion and M&A Potential
Aurinia Pharmaceuticals Analyst Ratings
Aurinia Pharmaceuticals Price Target Maintained With a $10.00/Share by Cantor Fitzgerald
Aurinia Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Aurinia Pharmaceuticals, Maintains $13 Price Target
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $13
Buy Rating Affirmed for Aurinia Pharmaceuticals on AUR200's Clinical and Financial Promise
RBC Capital Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $8
Analysts Have Conflicting Sentiments on These Healthcare Companies: UniQure (QURE), Aurinia Pharmaceuticals (AUPH) and Vertex Pharmaceuticals (VRTX)
Aurinia Pharmaceuticals (AUPH) Receives a Buy From RBC Capital
H.C. Wainwright Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $13
TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $11
Aurinia Pharmaceuticals: Strong Q2 Sales and Market Penetration Back Buy Rating
No Data